Updating results

249 results

Sort: Relevance | Date

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Key points The content of this evidence summary

Evidence summary Published April 2017

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

Evidence summary Published March 2016

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Antimicrobial prescribing: meropenem with vaborbactam (ES21)

Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

Evidence summary: antimicrobial prescribing Published November 2019

Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

Evidence summary: antimicrobial prescribing Published December 2019

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Biosimilar medicines (KTT15)

The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated February 2018

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Laxatives (KTT1)

The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015

Non-steroidal anti-inflammatory drugs (KTT13)

The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2018

Minocycline (KTT11)

The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015

Wound care products (KTT14)

This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Renin-angiotensin system drugs: dual therapy (KTT2)

The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2016

Safer insulin prescribing (KTT20)

This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2018 Last updated September 2019

Shared decision making (KTT23)

This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Lipid-modifying drugs (KTT3)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Hypnotics (KTT6)

This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2016

Antimicrobial stewardship: prescribing antibiotics (KTT9)

This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

Evidence summary Published July 2013

Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)

The key therapeutic topic 3-day courses of antibiotics for uncomplicated urinary tract infection has been retired from the 2017 update of medicines optimisation: key therapeutic topics. Key points have been incorporated into the antimicrobial stewardship topic. See the key therapeutic topic antimicrobial stewardship: prescribing antibiotics for more information.

Key therapeutic topic Published January 2015

Omega-3 fatty acid supplements (KTT4)

The key therapeutic topic omega-3 fatty acid supplements has been incorporated into the key therapeutic topic lipid-modifying drugs. See lipid-modifying drugs for more information.

Key therapeutic topic Published January 2015

The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

Advice on the use of the Juxta CURES adjustable compression system for treating venous leg ulcers to aid local decision-making

Medtech innovation briefing Published March 2015

The PediGuard for placing pedicle screws in spinal surgery (MIB26)

Advice on the use of the PediGuard for placing pedicle screws in spinal surgery to aid local decision-making

Medtech innovation briefing Published March 2015

Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

Advice on the use of the Xpert GBS test for the intrapartum detection of group B streptococcus (GBS) colonisation in pregnant women...

Medtech innovation briefing Published April 2015

LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

Advice on the use of the LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands to aid local decision-making

Medtech innovation briefing Published April 2015

LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

Advice on the use of the LARS (ligament augmentation and reconstruction system) for reconstructing damaged intra-articular cruciate knee ligaments...

Medtech innovation briefing Published May 2015

Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

Advice on the use of the Peptest for diagnosing gastro-oesophageal reflux disease (GORD) to aid local decision-making

Medtech innovation briefing Published May 2015